KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Net Margin (2016 - 2025)

Acadia Pharmaceuticals has reported Net Margin over the past 16 years, most recently at 96.33% for Q4 2025.

  • Quarterly results put Net Margin at 96.33% for Q4 2025, up 4096.0% from a year ago — trailing twelve months through Dec 2025 was 36.49% (up 1285.0% YoY), and the annual figure for FY2025 was 36.49%, up 1285.0%.
  • Net Margin for Q4 2025 was 96.33% at Acadia Pharmaceuticals, up from 25.76% in the prior quarter.
  • Over the last five years, Net Margin for ACAD hit a ceiling of 96.33% in Q4 2025 and a floor of 97.91% in Q1 2022.
  • Median Net Margin over the past 5 years was 5.16% (2021), compared with a mean of 6.77%.
  • Biggest five-year swings in Net Margin: plummeted -3555bps in 2022 and later soared 6159bps in 2023.
  • Acadia Pharmaceuticals' Net Margin stood at 32.96% in 2021, then rose by 7bps to 30.54% in 2022, then surged by 165bps to 19.82% in 2023, then skyrocketed by 179bps to 55.37% in 2024, then skyrocketed by 74bps to 96.33% in 2025.
  • The last three reported values for Net Margin were 96.33% (Q4 2025), 25.76% (Q3 2025), and 10.08% (Q2 2025) per Business Quant data.